Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagl
- PDF / 937,252 Bytes
- 11 Pages / 595.276 x 790.866 pts Page_size
- 38 Downloads / 202 Views
ORIGINAL RESEARCH ARTICLE
Imeglimin Does Not Induce Clinically Relevant Pharmacokinetic Interactions When Combined with Either Metformin or Sitagliptin in Healthy Subjects Pascale Fouqueray1 · Sandrine Perrimond‑Dauchy1 · Sébastien Bolze1
© Springer Nature Switzerland AG 2020
Abstract Background and Objectives Imeglimin (IMEG) is the first in a novel class of oral glucose-lowering agents with a unique mechanism of action targeting mitochondrial bioenergetics. We assessed whether repeated co-administration of IMEG and either metformin (MET) or sitagliptin (SITA) would influence the pharmacokinetics of either MET or SITA in healthy Caucasian men. Methods Healthy Caucasian men received either MET 850 mg twice daily with placebo (n = 16) or SITA 100 mg once daily with placebo (n = 16) on days 1–6, followed by MET 850 mg twice daily with IMEG 1500 mg twice daily or SITA 100 mg once daily with IMEG 1500 mg twice daily on days 7–12. Pharmacokinetic parameters were determined from blood and urine; levels of all compounds were evaluated using liquid chromatography with tandem mass spectrometry. Results Systemic exposure (AUC0–τ area under the plasma concentration-time curve over a dosing interval and maximum concentration) to MET was 14% and 10% lower, respectively, when administered with IMEG. Approximately 40% of MET was excreted unchanged in urine, decreasing to 34% when given with IMEG. The 90% confidence intervals for AUC0–τ and maximum concentration indicated no effect of co-administration on systemic exposure to MET. Mean AUC0–τ and maximum concentration of SITA were similar with or without IMEG. Median times to maximum concentration were 0.7 and 1.0 h and mean elimination half-lives were 8.2 and 8.7 h with and without IMEG, respectively. Systemic exposure to IMEG was similar to previous phase I studies. Conclusions Co-administration of IMEG with MET or SITA did not result in clinically relevant changes in systemic exposure to MET or SITA, although minor reductions in exposure (AUC0–τ and maximum concentration) and renal elimination were noted when MET was given with IMEG vs placebo. Clinical Trial Registration EudraCT2009-014520-40 (MET-IMEG DDI) and EudraCT2010-022926-34 (SITA-IMEG DDI)
1 Introduction Type 2 diabetes mellitus (T2DM) is a progressive metabolic disorder characterized by β-cell failure on the background of insulin resistance, with most patients eventually requiring combination therapies to maintain adequate glycemic control [1]. Imeglimin (IMEG) is the first in a new class of oral antidiabetic agents known as glimins, and is efficacious as monotherapy in clinical studies with a favorable tolerability profile [2]. Add-on studies suggest that the addition of IMEG to metformin (MET) or sitagliptin (SITA) is associated with * Sébastien Bolze [email protected] 1
Poxel SA, 259/261 Avenue Jean Jaurès, 69007 Lyon, France
benefits in efficacy and was well tolerated, highlighting the potential for IMEG to complement other antihyperglycemic treatments [3, 4]. Imeglimin targets mit
Data Loading...
